Art. -Nr.: HY-16450

Copy Link Print Information

SB 204990

26 Cited Publications

Kundenbewertung

Based on 26 publication(s) in Google Scholar

SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.75%
CAS. Nr.: 154566-12-8
Formel: C₁₈H₂₂Cl₂O₅
Molecular Weight:389.27

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

SB 204990 Chemical Structure

CAS. Nr.: 154566-12-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.

IC₅₀ & Target

ACLY^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	24 μM Compound: 16; SB-204990	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 30195238]
PC-3	IC₅₀	26 μM Compound: 16; SB-204990	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 30195238]
SK-OV-3	IC₅₀	53 μM Compound: 16; SB-204990	Antiproliferative activity against human SKOV3 cells Antiproliferative activity against human SKOV3 cells	[PMID: 30195238]

In Vitro

SB204990 (SB) is a specific inhibitor of ACLY enzyme. SB204990 treatment leads to a decrease in cytosolic Ac-CoA level and is thus expected to decrease acetylated and active β-catenin levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB 204990, when administered orally to rats, is absorbed into the systemic circulation. When administered in the diet (0.05-0.25%, w/w) for 1 week, SB 204990 causes a dose-related decrease in plasma cholesterol (by up to 46%) and triglyceride levels (by up to 80%) in rats. SB 204990 (25 mg/kg per day) also decreases plasma cholesterol levels (by up to 23%) and triglyceride levels (by up to 38%) in the dog, preferentially decreasing low-density lipoprotein compared with high-density lipoprotein cholesterol levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 154566-12-8
Appearance Solid
Molecular Weight 389.27
Formel C₁₈H₂₂Cl₂O₅
Color White to off-white
SMILES

O=C(O)C[C@]1(O)C(O[C@H](CCCCCCC2=CC=C(Cl)C=C2Cl)C1)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (26)

All Bio/Physico-chemical AssayFlow CytometryWBRT-PCR

Sort by:

Journal Impact Factor

Nature

Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy. [Abstract]

2026 Jan;649(8098):1022-1031. PMID: 41225001

SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]

SB 204990 (SB, 100 μM, 16 h) reduced cytosolic AcCoA levels in HeLa-tet-on-mt-Keima cells.

SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]

SB 204990 (SB, 100 μM, 16 h) enhanced mitophagy, as indicated by an increase in the acidic mt-Keima signal in HeLa-tet-on-mt-Keima cells.

SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]

SB 204990 (SB, 100 μM, 16 h) increased LC3 expression and decreased TIM23 and MT-CO2 levels in HeLa-tet-on-mt-Keima cells.

SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]

SB 204990 (SB, 100 μM, 16 h) increased the acidic mt-Keima signal in MCF7 and A549 cells.

SB 204990 purchased from MedChemExpress. Usage Cited in: Nature. 2026 Jan;649(8098):1022-1031. [Abstract]

SB 204990 (SB, 100 μM, 16 h) decreased mitochondrial mass in MCF7, A549, and HeLa cells.
Cell Metab

Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. [Abstract]

2023 Jan 3;35(1):200-211.e9. PMID: 36309010
Nat Protoc

Comprehensive multiscale analysis of lactate metabolic dynamics in vitro and in vivo using highly responsive biosensors. [Abstract]

2024 May;19(5):1311-1347. PMID: 38307980
Adv Sci (Weinh)

Extracellular Vesicle-Transferred ATP-Citrate Lyase Induces Monocyte Differentiation Toward Tumor-Associated Macrophages and Fuels Hepatocellular Carcinoma Progression. [Abstract]

2026 Jun;13(35):e21458. PMID: 41995119
Adv Sci (Weinh)

The Nuclear Localization of ACLY Guards Early Embryo Development Through Recruiting P300 and HAT1 to Promote Histone Acetylation and Transcription. [Abstract]

2025 Aug;12(31):e14367. PMID: 40470746
Adv Sci (Weinh)

MSL1 Promotes Liver Regeneration by Driving Phase Separation of STAT3 and Histone H4 and Enhancing Their Acetylation. [Abstract]

2023 Aug;10(23):e2301094. PMID: 37279389
Cell Death Dis

ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer. [Abstract]

2025 Dec 18. PMID: 41413018
Cell Death Dis

A targetable antioxidant defense mechanism to EZH2 inhibitors enhances tumor cell vulnerability to ferroptosis. [Abstract]

2025 Apr 14;16(1):291. PMID: 40229247
Pharmacol Res

Pharmacological induction of mesenchymal-epithelial transition via inhibition of H2S biosynthesis and consequent suppression of ACLY activity in colon cancer cells. [Abstract]

2021 Mar:165:105393. PMID: 33484818
J Pharm Anal

Tanshinone IIA ameliorates energy metabolism dysfunction of pulmonary fibrosis using 13C metabolic flux analysis. [Abstract]

2024 Feb;14(2):244-258. PMID: 38464785
Oncogene

SLC7A5-ERBB2 axis drives olaparib resistance via de novo lipid synthesis in ovarian cancer. [Abstract]

2025 Nov 28. PMID: 41315667
Apoptosis

Mitochondrial CLPB is a pro-survival factor at the onset of granulocytic differentiation of mouse myeloblastic cells. [Abstract]

2025 Feb;30(1-2):334-348. PMID: 39644357
Int J Nanomedicine

A Graphene-Based Lipid Modulation Nanoplatform for Synergetic Lipid Starvation/Chemo/Photothermal Therapy of Oral Squamous Cell Carcinoma. [Abstract]

2024 Nov 4:19:11235-11255. PMID: 39524917
JACC Basic Transl Sci

ATP-Citrate Lyase Supports Cardiac Function and NAD+/NADH Balance and Is Depressed in Human Failing Myocardium. [Abstract]

2025 Jun 10;10(7):101301. PMID: 40499285
EMBO Mol Med

FADS1/2 control lipid metabolism and ferroptosis susceptibility in triple-negative breast cancer. [Abstract]

2024 Jul;16(7):1533-1559. PMID: 38926633
Cell Rep

Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. [Abstract]

2024 Nov 26;43(12):115015. PMID: 39602308
Cell Rep

Pyruvate metabolism controls chromatin remodeling during CD4+ T cell activation. [Abstract]

2023 Jun 1;42(6):112583. PMID: 37267106
Cell Rep

Blockage of citrate export prevents TCA cycle fragmentation via Irg1 inactivation. [Abstract]

2022 Feb 15;38(7):110391. PMID: 35172156
Liver Int

Inhibition of ACSS2 attenuates alcoholic liver steatosis via epigenetically regulating de novo lipogenesis. [Abstract]

2023 Aug;43(8):1729-1740. PMID: 37183518
Sci Rep

Contribution of glucose and glutamine to hypoxia-induced lipid synthesis decreases, while contribution of acetate increases, during 3T3-L1 differentiation. [Abstract]

2024 Nov 15;14(1):28193. PMID: 39548264
Sci Rep

Lipidome and metabolome analyses reveal metabolic alterations associated with MCF-7 apoptosis upon 4-hydroxytamoxifen treatment. [Abstract]

2023 Oct 29;13(1):18549. PMID: 37899460
Pathol Res Pract

ACLY: A biomarker of recurrence in breast cancer. [Abstract]

2020 Sep;216(9):153076. PMID: 32825949
Front Oncol

Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway. [Abstract]

2021 Mar 17:11:642229. PMID: 33816292
bioRxiv

2026 Feb 1.
bioRxiv

2023 Jul 3.
Research Square Preprint

2022 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (256.89 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 25 mg/mL (64.22 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5689 mL

12.8446 mL

25.6891 mL

5 mM

0.5138 mL

2.5689 mL

5.1378 mL

10 mM

0.2569 mL

1.2845 mL

2.5689 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.34 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 2.56 mg/mL (6.58 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Shares BH, et al. Active mitochondria support osteogenic differentiation by stimulating β-catenin acetylation. J Biol Chem. 2018 Oct 12;293(41):16019-16027. [Content Brief]

[2]. Pearce NJ, et al. The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076. Biochem J. 1998 Aug 15;334 ( Pt 1):113-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	2.5689 mL	12.8446 mL	25.6891 mL	64.2228 mL
	5 mM	0.5138 mL	2.5689 mL	5.1378 mL	12.8446 mL
	10 mM	0.2569 mL	1.2845 mL	2.5689 mL	6.4223 mL
	15 mM	0.1713 mL	0.8563 mL	1.7126 mL	4.2815 mL
	20 mM	0.1284 mL	0.6422 mL	1.2845 mL	3.2111 mL
	25 mM	0.1028 mL	0.5138 mL	1.0276 mL	2.5689 mL
	30 mM	0.0856 mL	0.4282 mL	0.8563 mL	2.1408 mL
	40 mM	0.0642 mL	0.3211 mL	0.6422 mL	1.6056 mL
	50 mM	0.0514 mL	0.2569 mL	0.5138 mL	1.2845 mL
	60 mM	0.0428 mL	0.2141 mL	0.4282 mL	1.0704 mL
DMSO	80 mM	0.0321 mL	0.1606 mL	0.3211 mL	0.8028 mL
DMSO	100 mM	0.0257 mL	0.1284 mL	0.2569 mL	0.6422 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

SB 204990

26 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

SB 204990

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Metabolism/Protease Compound Library

Publications Citing Use of MedChemExpress (MCE) SB 204990

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SB 204990

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Metabolism/Protease Compound Library

Publications Citing Use of MedChemExpress (MCE) SB 204990

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

SB 204990 Related Classifications

HY-16450 Related Classifications